1. E. Mamcarz et al., Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med 380, 1525-1534 (2019).
2. D. B. Kohn et al., Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med 26, 200-206 (2020).
3. S. S. De Ravin et al., Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 8, 335ra357 (2016).
4. A. Aiuti et al., Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).
5. A. Biffi et al., Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013).
6. C. J. Braun et al., Gene therapy for Wiskott-Aldrich Syndrome-Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis. Rare Dis 2, e947749 (2014).
7. S. J. Howe et al., Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118, 3143-3150 (2008).
8. S. Hacein-Bey-Abina et al., A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348, 255-256 (2003).
9. S. Hacein-Bey-Abina et al., LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
10. M. Cavazzana-Calvo et al., Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322 (2010).
11. A. Moiani et al., Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 122, 1653-1666 (2012).
12. R. K. Merling et al., Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 121, e98-107 (2013).
13. D. Viskochil et al., Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187-192 (1990).
14. M. R. Wallace et al., Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181-186 (1990).
15. M. Bosticardo et al., Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia. Blood Adv 4, 2611-2616 (2020).
16. M. Cavazzana, F. D. Bushman, A. Miccio, I. Andre-Schmutz, E. Six, Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat Rev Drug Discov 18, 447-462 (2019).
17. S. Hacein-Bey-Abina et al., Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118, 3132-3142 (2008).
18. M. Bokhoven et al., Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol 83, 283-294 (2009).
19. S. Knight, M. Bokhoven, M. Collins, Y. Takeuchi, Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat. J Virol 84, 4856-4859 (2010).
20. D. Cesana et al., Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 122, 1667-1676 (2012).
21. E. Montini et al., The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119, 964-975 (2009).
22. A. Fusco, M. Fedele, Roles of HMGA proteins in cancer. Nat Rev Cancer 7, 899-910 (2007).
23. R. Sgarra et al., Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 574, 1-8 (2004).
24. M. R. Copley et al., The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nat Cell Biol 15, 916-925 (2013).
25. P. Kumar et al., HMGA2 promotes long-term engraftment and myeloerythroid differentiation of human hematopoietic stem and progenitor cells. Blood Adv 3, 681-691 (2019).
26. J. Nishino, I. Kim, K. Chada, S. J. Morrison, Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 135, 227-239 (2008).
27. J. Nishino, S. Kim, Y. Zhu, H. Zhu, S. J. Morrison, A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties. Elife 2, e00924 (2013).
28. G. P. Wang, A. Ciuffi, J. Leipzig, C. C. Berry, F. D. Bushman, HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res 17, 1186-1194 (2007).
29. A. R. Young, M. Narita, Oncogenic HMGA2: short or small? Genes Dev 21, 1005-1009 (2007).
30. K. Ikeda, P. J. Mason, M. Bessler, 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 117, 5860-5869 (2011).
31. F. C. Yang et al., Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 135, 437-448 (2008).
32. R. K. Merling et al., Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 121, e98-107 (2013).
33. C. S. Seet et al., Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat Methods 14, 521-530 (2017).
34. H. Fujisaki et al., Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69, 4010-4017 (2009).